THE VISIBLE 2 PHASE 3 STUDY OF EFFICACY AND SAFETY OF VEDOLIZUMAB SC FOR MODERATE-TO-SEVERE CROHN'S DISEASE

被引：0
|
作者：
Vermeire, Severine
D'Haens, Geert R.
Baert, Filip J.
Danese, Silvio
Kobayashi, Taku
Loftus, Edward V.
Bhatia, Siddharth
Kisfalvi, Krisztina
Rosario, Maria
Zhang, Wenwen
Sandborn, William J.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
950
引用
收藏
页码：S194 / S194
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study
    Vermeire, S.
    Sandborn, W.
    Baert, F.
    Danese, S.
    Kobayashi, T.
    Loftus, E. V., Jr.
    Bhatia, S.
    Kisfalvi, K.
    Rosario, M.
    Zhang, W.
    D'Haens, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S020 - S021
  • [2] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [3] Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease
    Viola, Franca
    Civitelli, Fortunata
    Di Nardo, Giovanni
    Barbato, Maria Beatrice
    Borrelli, Osvaldo
    Oliva, Salvatore
    Conte, Francesca
    Cucchiara, Salvatore
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2566 - 2571
  • [4] Comparative Efficacy and Safety of Adalimumab vs Vedolizumab in Managing Moderate-to-Severe Crohn's Disease: A Systematic Review and Meta-Analysis
    Merza, Nooraldin
    Al-Hillan, Alsadiq
    Mansur, Sarmed
    Merza, Fatima A.
    Nawras, Mohamad
    Dahiya, Dushyant Singh
    Boujemaa, Safa
    Naguib, Tarek
    Kobeissy, Abdallah A.
    Hassan, Mona
    Islam, Asm
    Alastal, Yaseen
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S705 - S706
  • [5] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    [J]. ADVANCES IN THERAPY, 2021, 38 (08) : 4233 - 4245
  • [6] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
    Ting Zhou
    Yanan Sheng
    Haijing Guan
    [J]. Advances in Therapy, 2021, 38 : 4233 - 4245
  • [7] Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis
    Merza, Nooraldin
    Nawras, Yusuf
    Saab, Omar
    Dahiya, Dushyant Singh
    Ahmed, Zohaib
    Ranabothu, Meghana
    Boujemaa, Safa
    Hassan, Mona
    Kobeissy, Abdallah
    Lilley, Kirthi
    [J]. GASTROENTEROLOGY RESEARCH, 2023, 16 (06) : 289 - 306
  • [8] A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn's disease
    Weisshof, R.
    Vavricka, S.
    Pouillon, L.
    Braegger, F.
    Roset, M.
    Bent-Ennakhil, N.
    Ferrante, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S317 - S318
  • [9] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
    Ogata, Haruhiko
    Motoya, Satoshi
    Watanabe, Kenji
    Kanai, Takanori
    Matsui, Toshiyuki
    Suzuki, Yasuo
    Shikamura, Mitsuhiro
    Sugiura, Kenkichi
    Oda, Kazunori
    Hori, Tetsuharu
    Araki, Takahiro
    Watanabe, Mamoru
    Hibi, Toshifumi
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S1109 - S1109
  • [10] Effectiveness, safety and durability of vedolizumab in active moderate-severe Crohn's Disease
    Morales Bermudez, A. I.
    Bracho Gonzalez, M.
    Gomez Rodriguez, P.
    Olmedo Martin, R.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I489 - I490
12345